Navigation Links
Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
Date:9/3/2009

SUNNYVALE, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that Dr. Glenn Rice, President and COO, will provide a business overview at the following conferences:

-- Thomas Weisel Partners 2009 Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 9th at 3:50 p.m. EDT.

-- Rodman & Renshaw 11th Annual Healthcare Conference at the Palace Hotel in New York on Thursday, September 10th at 12:05 p.m. EDT.

There will be a live webcast of the presentations, which will be accessible through a link posted on the investor relations / events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm. The webcasts will be available for replay through October 10th, 2009.

About Pharmacyclics

Pharmacyclics((R)) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in c
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Pharmacyclics, Inc. Rights Offering Oversubscribed
2. Pharmacyclics Announces Subscription Price for Rights Offering
3. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
4. Pharmacyclics Files Registration Statement for Rights Offering
5. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
6. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
7. Pharmacyclics Secures $5.0 Million in Debt Financing
8. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
9. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
10. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
11. Pharmacyclics Announces It Received Nasdaq Notification

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...dge, Mass November 30, 2009 An international tea...otonics, and ETH Zrich have demonstrated compact, ... the invisible part of the light spectrum (infrare...t beam of a well-defined wavelength. The innovativ...ons related to remote chemical sensing pollution m...
(Date:11/30/2009)..., NEW YORK, Nov. 30 Th...ch (MJFF) today announced $1.5 million in total aw...ntially disease-modifying therapies for Parkinson,...l Approaches to Drug Discovery for Parkinson,s Dis...Corporation, plc (NYSE: ELN ), a neuroscience-ba...
(Date:11/30/2009)..., AMSTERDAM, November 30 Biop...y that the first patients have been enrolled in it...TIR(TM). The study is,designed to show reduction i...r following an allogeneic stem cell transplantatio...od cancer patients eligible for an allogeneic,stem...
(Date:11/30/2009)..., ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ ...it has completed enrollment in the Phase II clinic.../2009 recommended strains) VLP vaccine candidate i...dults). This randomized, double-blind, active-con...y and immunogenicity of two different doses (15 mc...
Breaking Biology Technology:Scientists demonstrate multibeam, multi-functional lasers 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4
...debilitating illnesses, such as spinal cord injur...e, sclerosis and ataxia stand to benefit from a n...nment grant. Such a facility will put China at the...ogram human stem cells for p...ua-PRNewswire/ -- Beike Biotechnology, (, http://w...
...rch, Inc.,(Scimitar) issues a review of Neurobiolo... "Injecting Confidence to the Viprinex(TM) Mission.... This review is available at our website: http:...logies, Inc. (NTII) is a biotechnology company,eng...entral nervous system,related drug candidates. NTI...
...Inc.,(Nasdaq: BNVI ) today announced financial re...September 30, 2007. Third Quarter Results The co... September 30,2007 of $243,375 compared to $3,750 ... $239,625 over the comparable period in 2006, repr...awdown from the Department of Health,and Human Ser...
Other Biology Technology:Stem Cell Leader Beike Biotech and China's Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory 2Stem Cell Leader Beike Biotech and China's Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory 3Stem Cell Leader Beike Biotech and China's Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory 4Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc. 2Bionovo Announces Third Quarter 2007 Financial Results 2Bionovo Announces Third Quarter 2007 Financial Results 3Bionovo Announces Third Quarter 2007 Financial Results 4Bionovo Announces Third Quarter 2007 Financial Results 5Bionovo Announces Third Quarter 2007 Financial Results 6Bionovo Announces Third Quarter 2007 Financial Results 7
(Date:11/30/2009)...s a colorless and odorless radioactive gas that is...um is a product of uranium decay and is found in t... and groundwater as well as building materials, pl...entration is expressed as the amount of radiation ...cts in a liter of air; thus the units are picocuri...
(Date:11/26/2009)...r their impressive antlers, red deer have been cau...deer,s antlers are much more than decorative. They... duelling. John Currey, from The University of Yor...ties of bone for over half a century and has becom...r through a long-standing collaboration with Tomas...
(Date:11/26/2009)...carried out in eight European countries has shown ... disease pandemic could have a significant role in...g in the open access journal BMC Infectious Disea...l days and weekends/holidays, finding that they we...rom Hasselt and Antwerp University, Belgium, led a...
Breaking Biology News(10 mins):Health Physics Society recommends considering action for indoor radon below current guidelines 2Tough yet stiff deer antler is materials scientist's dream 2School closure could reduce swine flu transmission by 21 percent 2Let Kids Sleep Late on Weekends to Fight Fat 3A Study 60231 1Let Kids Sleep Late on Weekends to Fight Fat 3A Study 60231 2Let Kids Sleep Late on Weekends to Fight Fat 3A Study 60231 3China Pharma Holdings Inc to Report Third Quarter 2009 Financial Results on November 12 2009 60226 1China Pharma Holdings Inc to Report Third Quarter 2009 Financial Results on November 12 2009 60226 2Winner Medicals Subsidiary Won Contribution in Chinese Nonwovens and Industrial Textiles Industry Award 60221 1Winner Medicals Subsidiary Won Contribution in Chinese Nonwovens and Industrial Textiles Industry Award 60221 2Winner Medicals Subsidiary Won Contribution in Chinese Nonwovens and Industrial Textiles Industry Award 60221 3
...ed a new genetic mutation responsible for osteogen... much more likely to break, according to a study p...y experience just a few fractures in a lifetime or...r of Americans affected is unknown, but estimates ... important early step in the search for a cure, it...
...fluctuations in fish populations leaving them in d...ed today. These fluctuations mean current measures...ient to ensure their sustainability. , The resear... compiling the largest ever survey of both exploit...coast. The research team looked at how the abundan...
...versity of Kentucky, and Dr. Balamurali Ambati, of...ished a paper in the journal Nature detailing majo... angiogenesis. , In their paper published online ...at unravels the mystery of how a healthy cornea re...sential for vision, and raises questions about the...
Other Biology News:Researchers discover new gene responsible for brittle bone disease 2Researchers discover new gene responsible for brittle bone disease 3Commercial fishing causes dangerous fluctuations in fish populations 2Intrinsic eye protein halts angiogenesis 2
Flashlight-Trigger Solution from Assay Designs/Stressgen Bioreagents
...lity shift assay (EMSA) is a powerful tool for eva...o as gel shift or gel retardation, the assay is ba...ophoresis, free DNA will migrate differently than ...luminescent EMSA Kit is a nonradioactive system fo...
...real-time PCR detection system holds 48 x 0.2 ml t... independently excites fluorescence (470-500 nm) f...etects emitted light (523-543 nm and 540-700 nm). ... MJ Mini thermal cycler. System dimensions are 18 ...
... provide automated, higher throughput screening of...tubes. This flexible sample format makes the Guava...rch, target validation, assay development, and eve...uava PCA-96 uses a green laser detection system an...
Biology Products: